CuriosityStream And Two Other Promising Penny Stocks To Watch

Over the last 7 days, the U.S. market has dropped by 1.2%, but it has shown an impressive rise of 11% over the past year, with earnings projected to grow annually by 17%. In light of these conditions, identifying stocks that combine affordability with growth potential is crucial for investors seeking opportunities beyond established names. Although often seen as a relic from earlier market times, penny stocks still offer a unique investment avenue; they typically represent smaller or newer companies that can provide both value and potential upside when backed by strong financials.

Let's review some notable picks from our screened stocks.

CuriosityStream (CURI)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: CuriosityStream Inc. is a media and entertainment company that offers factual content across various channels, with a market cap of approximately $165 million.

Operations: The company generates $75.96 million in revenue from its media and entertainment offerings that provide factual content across various channels.

Market Cap: $164.96M

CuriosityStream Inc. has recently become profitable, reporting a significant increase in net income to US$8.88 million for the second quarter of 2026. The company is debt-free, which eliminates concerns over interest payments and highlights its financial prudence. However, its short-term liabilities exceed short-term assets by US$4.5 million, indicating potential liquidity challenges. Despite trading at a substantial discount to estimated fair value and analysts predicting an 85% price increase, the stock remains volatile with high weekly fluctuations compared to peers. The recent CFO transition may bring strategic financial oversight that aligns with growth objectives amidst these dynamics.

• Unlock comprehensive insights into our analysis of CuriosityStream stock in this financial health report.
• Assess CuriosityStream's future earnings estimates with our detailed growth reports.

AC Immune (ACIU)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: AC Immune SA is a clinical-stage biopharmaceutical company focused on discovering, designing, and developing medicines and products for neurodegenerative diseases related to protein misfolding, with a market cap of $245.58 million.

Operations: The company generates revenue of CHF 17.51 million from its segment focused on discovering and developing therapeutic and diagnostic products.

Market Cap: $245.58M

AC Immune SA, a clinical-stage biopharmaceutical company, is advancing its pipeline with promising developments in neurodegenerative disease treatments. Recent positive Phase 2 trial results for ACI-7104 in early-stage Parkinson’s disease demonstrate strong safety and immunogenicity, bolstered by FDA Fast Track designation. The company maintains a solid financial position with CHF93.4 million in short-term assets but faces challenges covering CHF100.2 million in short-term liabilities and remains unprofitable despite reducing losses over five years at 7% annually. With no debt and sufficient cash runway exceeding one year, AC Immune continues to focus on long-term growth potential amidst ongoing clinical trials.

• Click here and access our complete financial health analysis report to understand the dynamics of AC Immune.
• Learn about AC Immune's future growth trajectory here.

SmartRent (SMRT)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: SmartRent, Inc. is an enterprise real estate technology company offering management software and applications to rental property stakeholders globally, with a market cap of $231.85 million.

Operations: The company's revenue is primarily generated from its Electronic Security Devices segment, which amounts to $151.20 million.

Market Cap: $231.85M

SmartRent, Inc. has demonstrated revenue growth with US$39.84 million reported in Q2 2026, though it remains unprofitable with a net loss of US$5.64 million for the same period. The company has actively engaged in share repurchases, completing a buyback of 23,050,000 shares worth US$36.86 million since March 2024. Despite negative return on equity and an inexperienced management team averaging just over a year in tenure, SmartRent is debt-free and maintains short-term assets exceeding liabilities by a significant margin. Analysts generally agree on potential stock price appreciation by 25%, indicating market optimism despite current financial challenges.

• Take a closer look at SmartRent's potential here in our financial health report.
• Understand SmartRent's earnings outlook by examining our growth report.

Next Steps

• Unlock our comprehensive list of 328 US Penny Stocks by clicking here.
• Interested In Other Possibilities? Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com